King Wealth Management Group’s Teva Pharmaceuticals TEVA Stock Holding History

King Wealth Management Group’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.39M	Sell	100,000 -10,000	-9%	-$333K	0.37%	42
2026 Q1	$3.31M	Sell	110,000 -25,000	-19%	-$804K	0.41%	41
2025 Q4	$4.21M	Sell	135,000 -25,000	-16%	-$616K	0.51%	36
2025 Q3	$3.23M	Sell	160,000 -45,000	-22%	-$790K	0.41%	39
2025 Q2	$3.44M	Buy	205,000 +30,000	+17%	+$484K	0.47%	37
2025 Q1	$2.69M	Buy	175,000 +160,500	+1,107%	+$2.87M	0.41%	39
2024 Q4	$3.2M	Sell	14,500 -83,602	-85%	-$1.52M	0.47%	40
2024 Q3	$1.77M	Buy	+98,102	New	+$1.72M	0.28%	44
2016 Q2	–	Sell	-23,357	Closed	-$1.25M	–	108
2016 Q1	$1.25M	Sell	23,357 -599	-3%	-$35.1K	0.67%	34
2015 Q4	$1.57M	Sell	23,956 -576	-2%	-$35.6K	0.87%	28
2015 Q3	$1.39M	Buy	24,532 +859	+4%	+$55.7K	0.85%	28
2015 Q2	$1.4M	Sell	23,673 -649	-3%	-$40K	0.77%	31
2015 Q1	$1.51M	Sell	24,322 -4,498	-16%	-$262K	0.87%	28
2014 Q4	$1.66M	Buy	28,820 +1,508	+6%	+$84K	0.88%	31
2014 Q3	$1.47M	Buy	27,312 +352	+1%	+$18.6K	0.92%	28
2014 Q2	$1.42M	Buy	26,960 +636	+2%	+$32.5K	0.88%	30
2014 Q1	$1.39M	Buy	+26,324	New	+$1.22M	0.96%	27

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

King Wealth Management Group's TEVA Position: Q2 2026 in Review

King Wealth Management Group reduced its Teva Pharmaceuticals (TEVA) stake by 9.1% in Q2 2026, selling an estimated $333K and leaving 100,000 shares worth $3.39M. The position accounts for 0.37% of the portfolio, ranked #42.

King Wealth Management Group first reported a position in TEVA in Q1 2014 and has held it in 17 quarters since. The position peaked at $4.21M in Q4 2025. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

King Wealth Management Group held 100,000 shares of Teva Pharmaceuticals worth $3.39M as of Q2 2026.
King Wealth Management Group sold 10,000 Teva Pharmaceuticals shares in Q2 2026, an estimated $333K.
Teva Pharmaceuticals made up 0.37% of King Wealth Management Group's portfolio in Q2 2026, its #42 holding.
King Wealth Management Group first reported a position in Teva Pharmaceuticals in Q1 2014 and has held it in 17 quarters since.
King Wealth Management Group's Teva Pharmaceuticals position peaked at $4.21M in Q4 2025.
672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on King Wealth Management Group's 13F filing for Q2 2026, filed 5 Aug 2026.